Radiolabeling and preclinical evaluation of technetium-99m labeled colistin

Pardeep Kumar,Nagesh C Shanbhag#,Pradip Chaudhari,Bhabani Mohanty,Riptee Thakur,Gopalakrishnan M Sasidharan

DOI: https://doi.org/10.1016/j.apradiso.2024.111524

IF: 1.787

2024-09-19

Applied Radiation and Isotopes

Abstract:Introduction Antibiotic resistance is a burden on the healthcare system. In present study, we have labeled an antibiotic named Colistimethate sodium (CMS) with technetium-99m ( 99m Tc) to develop a SPECT based imaging tracer. Methods We standardised the labeling using 0.5–2 mg of CMS (in water) using stannous chloride dihydrate as a reducing agent followed by addition of 370 ± 74 MBq of 99m Tc. A group of mice were injected intravenously (in tail vein) with 4–6 MBq of [ 99m Tc]Tc-CMS diluted with saline and euthanized at various time intervals. microSPECT Imaging (Υ-eye) was acquired to study the biodistribution in the healthy mice. Results We standardised the labeling using 0.5 mg of colistin in 0.5 ml of saline with addition of 30 μg stannous chloride dihydrate. The retention factor value was 0.1–0.3 as compared to 0.9–1.0 for free 99m Tc by TLC and retention time was found to be 14.2 ± 1.3 min as evaluated by HPLC. The biodistribution data showed uptake in lungs, spleen, and liver at 30 min but the uptake decreased in lung at 60 min. The imaging data corroborated with the biodistribution data. Conclusions We could successfully label [ 99m Tc]Tc-CMS 99m Tc and we could study its biodistribution in healthy mice.

radiology, nuclear medicine & medical imaging,nuclear science & technology,chemistry, inorganic & nuclear